Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 47 Breast Neoplasms 39 Ovarian Neoplasms 35 Triple Negative Breast Neoplasms 24 Endometrial Neoplasms 20 Stomach Neoplasms 19 Squamous Cell Carcinoma of Head and Neck 17 Fallopian Tube Neoplasms 17 Lung Neoplasms 16 Esophageal Squamous Cell Carcinoma 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Neoplasm Metastasis 13 Esophageal Neoplasms 13 Neoplasms 12 Uterine Cervical Neoplasms 11 Carcinoma, Ovarian Epithelial 10 Head and Neck Neoplasms 7 Recurrence 6 Carcinoma 6 Colorectal Neoplasms 5 Adenocarcinoma 5 Uterine Neoplasms 4 Small Cell Lung Carcinoma 4 Oropharyngeal Neoplasms 4 Melanoma 4 Carcinoma, Transitional Cell 4 Advanced Solid Tumors 4 Adenocarcinoma Of Esophagus 4 Carcinoma, Squamous Cell 3 Carcinoma, Renal Cell 3

Interventions

liposomal doxorubicin 3 1-dodecylpyridoxal 2 pembrolizumab 1 mirabegron 1 disitamab vedotin 1 anlotinib 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ovarian Cancer Recurrent × Paclitaxel × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡